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Abstract
Background: Lentivector-mediated gene delivery into the dorsal root ganglion (DRG) is a promising method for
exploring pain pathophysiology and for genetic treatment of chronic neuropathic pain. In this study, a series of
modified lentivector particles with different cellular promoters, envelope glycoproteins, and viral accessory proteins
were generated to evaluate the requirements for efficient transduction into neuronal cells in vitro and adult rat
DRG in vivo.
Results: In vitro, lentivectors expressing enhanced green fluorescent protein (EGFP) under control of the human
elongation factor 1a (EF1a) promoter and pseudotyped with the conventional vesicular stomatitis virus G protein
(VSV-G) envelope exhibited the best performance in the transfer of EGFP into an immortalized DRG sensory neuron
cell line at low multiplicities of infection (MOIs), and into primary cultured DRG neurons at higher MOIs. In vivo,
injection of either first or second-generation EF1a-EGFP lentivectors directly into adult rat DRGs led to transduction
rates of 19 ± 9% and 20 ± 8% EGFP-positive DRG neurons, respectively, detected at 4 weeks post injection.
Transduced cells included a full range of neuronal phenotypes, including myelinated neurons as well as both non-
peptidergic and peptidergic nociceptive unmyelinated neurons.
Conclusion: VSV-G pseudotyped lentivectors containing the human elongation factor 1a (EF1a)-EGFP expression
cassette demonstrated relatively efficient transduction to sensory neurons following direct injection into the DRG.
These results clearly show the potential of lentivectors as a viable system for delivering target genes into DRGs to
explore basic mechanisms of neuropathic pain, with the potential for future clinical use in treating chronic pain.
Background
Chronic neuropathic pain may accompany numerous
disease states, but current treatments remain inadequate
[1]. There is increasing evidence that the primary sen-
sory neurons and their somata in the dorsal root gang-
lion (DRG) are critically important sites in the
generation of neuropathic pain [2]. Development of pain
management therapies to selectively target one or more
DRGs would have the clear benefits of directing therapy
at the specific involved anatomic pathway while limiting
effects on other neuronal populations.
The use of gene transfer vectors based on viruses has
emerged as an attractive molecular approach to thera-
peutically modify the genetic profiles of mammalian
cells, including those of the central nervous system [3].
Pre-clinical and clinical studies have begun to investi-
gate the potential use of non-integrating viral vectors,
such as herpes simplex virus type 1 (HSV-1) and various
serotypes of adeno-associated viral (AAV) vectors, for
neuropathic disorders [4-6], but their temporal persis-
tence within neuronal cells following cellular transduc-
tion in vivo is unproven. Moreover, humoral and innate
immune responses may also lead to a diminished biolo-
gical effect for either of these vector systems [7].
Towards this end, replication-defective lentiviral vec-
tors have been extensively studied for gene therapy
applications due to their intrinsic ability to integrate
into the host genome, allowing for stable and long-term
expression (up to or greater than 6 months) in termin-
ally differentiated neuronal tissue in many mammalian
species [8-10]. The need for a long-term therapy is an
important feature for any vector that is developed to
treat chronic pain. In addition, lentiviral vector
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physiological function [11-13]. Although there are sev-
eral studies demonstrating successful genetic
modification of cultured DRG neurons using lentiviral
vectors [14-16] there remains a paucity of data docu-
menting efficient transduction of lentiviral vectors into
sensory neurons in vivo.
The present study was designed to investigate the vec-
torological factors that may promote efficient DRG
transduction in vivo. This is a critical challenge, since it
is known that the efficiency of viral vector transduction
can be markedly diminished in vivo despite optimal per-
formance under in vitro conditions [17]. Our experi-
ments examined whether alterations in the lentiviral
vector system in terms of envelope coat proteins, viral
accessory genes, and internal promoter activity would
enhance transduction efficiency and the level of trans-
gene expression in DRG neurons in vitro and more
importantly, in vivo. In vivo delivery of vectors to the
DRG has been attempted by either direct or remote
injection. Specifically, a standard technique exists for
intra-DRG injection in human clinical subjects [18], and
we have recently devised a direct microinjection techni-
que to reliably and safely deliver high titers of rAAV
vector into the targeted DRG region [19]. Alternatively,
others have used remote muscle injection for rabies G
pseudotyped, but not VSV-G, lentivector deposition
[20], although this route preferentially transduced spinal
cord motor neurons with limited DRG transduction. In
the work reported here, we have compared these
approaches. On the basis of our findings, we have con-
cluded that lentiviral vector gene delivery holds great
promise for anatomically targeted manipulation of speci-
fic neuronal processes that contribute to pain.
Results
Optimizing in vitro performance of lentivectors
A panel of modified lentivectors was generated by alter-
ing several components in our system, specifically: 1)
internal cellular promoters, 2) viral accessory proteins,
and 3) envelope coat proteins (in a process known as
pseudotyping).
Constitutively active cellular promoters
As a first step in optimizing lentiviral vector-mediated
transduction of DRG neurons, we analyzed various cel-
lular promoters in the context of the lentivector.
Because of the inherent variability of primary culture
preparations, a cell line was used to initially compare
the vectorological performance of the lentivector system.
In these initial experiments, we used 50B11 cells, an
immortalized rat DRG sensory neuron cell line that
mimics the small-diameter subpopulation of DRG neu-
rons in vivo by expressing capsaicin-sensitive transient
receptor potential vanilloid-1 (TRPV1), and a-calcitonin
gene-related peptide (CGRP), binding isolectin IB4,
developing currents through TRPV1 channels, generat-
ing action potentials, and extending long neurites
[21,22]. We have found that these cells expressed
TRPV1 and binding IB4 in undifferentiating culture. As
reported, neuronal differentiation after forskolin induc-
tion were demonstrated in 50B11 cells and b3-tubulin
and CGRP were also positive in forskolin-induced differ-
entiated cells (data shown in Additional File 1).
Lentiviral vectors (Figure 1A) containing enhanced
green fluorescent protein (EGFP) as a marker gene were
cloned with four different cellular promoters, including
the human elongation factor 1a (EF1a) promoter, the
composite CAG promoter consisting of the CMV
immediate early enhancer and the chicken b-actin pro-
moter, the human ubiquitin C (UbC) promoter, and the
murine phosphoglycerate kinase 1 (PGK) promoter.
These cellular promoters are believed to be ubiquitously
active and have a range of promoter strength [23,24].
Viral promoters were not specifically analyzed in these
experiments due to their intrinsic propensity to down-
regulate following long-term transduction using various
viral and non-viral vector systems [25].
Preliminary experiments applying moderate viral doses
(MOI = 5 and 10) onto 50B11 cells resulted in high
transduction efficiency and EGFP fluorescent intensity,
but with low levels of cell survival, presumably due to
the overt toxicity associated with the vectors. In order
to improve both cell survival and overall transduction
efficiency, the subsequent experiments examining trans-
duction efficiencies were performed using serial trans-
duction steps at low MOI (MOI = 1) on two
consecutive days (one application per day), by which
toxicity of the lentivectors was minimized. Using this
approach, lentivectors containing EF1a-EGFP expression
cassette and packaged with the second-generation sys-
tem produced the most efficient transduction (95 ± 1%;
n = 4; P < 0.001) four days after the initial application,
compared to other lentivectors containing either the
CAG (65 ± 2%; n = 4), PGK (58 ± 2%; n = 4), or UbC
(40 ± 10%; n = 4) promoters (Figure 1B). These findings
s u g g e s tt h a tt h eE F 1 a promoter in the context of the
lentivector may be the most appropriate for expressing
transgenes of interest in DRG neurons.
Viral accessory proteins
To determine whether viral accessory proteins that are
normally found in wild-type lentiviruses, specifically vpr,
vpu, vif,a n dnef, can promote increased transduction
efficiency in DRG cells, we compared different versions
of the lentivector system in which accessory proteins
were either present or absent during vector production.
EF1a-EGFP vectors complexed with the first-generation
packaging system (LV1-EF1a-EGFP), which includes the
full complement of viral accessory proteins, produced
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However, vectors generated using the second-generation
system (LV2-EF1a-EGFP), which is relatively devoid of
the viral accessory proteins found in the first-generation
system, produced equally high transduction (93 ± 3%; n
= 8). These experiments suggest that viral accessory
proteins are not essential for high-efficiency transduc-
tion of sensory neurons.
Alternate pseudotypes
In the next set of experiments, we swapped the VSV-G
envelope with other glycoproteins in a process known as
pseudotyping, in order to determine whether changes in
the coat protein would alter the transduction efficiency.
Lentivectors containing the EF1a-EGFP expression cas-
sette were alternatively pseudotyped with various rhab-
doviruses (VSV-G; rabies virus Pasteur vaccine strain,
RABPV; and rabies virus SAD strain, RABSAD) or are-
navirus (lymphocytic choriomeningitis virus, LCMV)
glycoproteins, all packaged using the second-generation
system, to determine the transduction efficiency in cul-
tured 50B11 cells. The MOIs for each vector used on
the 50B11 cells were adjusted based on functional titers
(transducing units, TU) obtained from HeLa cells. As
shown in Figure 1D, the VSV-G pseudotyped lentivector
was the most efficient in transducing the 50B11 cells
(92 ± 2%; n = 4), which was significantly higher (P <
0.001) than the other pseudotypes tested in our experi-
ment, including RABPV (78 ± 4%; n = 4), RABSAD (23
± 2%; n = 4), and LCMV (35 ± 2%; n = 4). EGFP
expression images of 50B11 cells after transduction are
shown in Additional File 1.
Transduction of dissociated DRG cell cultures with
lentivectors
To confirm our findings from the 50B11 cell line, the
transduction efficiency of lentivectors into DRG neurons
was further tested in the primary cultures of DRG cells
dissociated from adult rats. Initially, the transduction
time course (1-10 days in vitro, DIV) and dose response
(increasing MOI from 1, 10, 20, 30, and 50) were opti-
mized using VSV-G pseudotyped second-generation len-
tivectors expressing EGFP driven by the EF1a promoter
(LV2-EF1a-EGFP), which exhibited highest transduction
rate in 50B11 cells. Unlike the 50B11 cells, primary
adult DRG cells were tolerant of the VSV-G pseudo-
typed lentivector at high MOI (MOI > 20). Overall, the
transduction events appeared as a function of time in
culture and virus does (data not shown). When cultures
were exposed to LV2-EF1a-EGFP at MOI = 1, only an
occasional transduction event was observed. At elevated
viral doses from MOI 10 to 50, EGFP expression
became evident in the cell body of neurons within 48 hr
after exposure to LV2-EF1a-EGFP. Increased transduc-
tion events were evident as a result of higher MOIs, and
EGFP expression appeared maximal after five days in
Figure 1 Lentiviral transduction of immortalized sensory
neuronal cells (50B11) in vitro. A. Schematic representation of the
lentivectors. EGFP-expressing lentivector (LV) plasmids carrying a
panel of various recombinant promoters were generated. Cis-acting
sequences included were cPPT (central polypurine tract) to enhance
transduction efficiency, and WPRE (woodchuck posttranscriptional
regulatory element) to improve transgene expression. B, C and D.
LV transduction efficiencies in 50B11 cells (MOI = 2) were assessed
by FACS analysis. B. Transduction efficiencies were compared
between vectors with different constitutively active cellular
promoters (n = 4 experiments/promoter), including: 1) human
elongation factor 1a (EF1a); 2) hybrid promoter containing a
human CMV enhancer element 5’ to the chicken b-actin promoter
(CAG); 3) human ubiquitin C (UbC); and 4) murine phosphoglycerate
kinase gene (PGK). C. Transduction efficiencies using LVs with (first-
generation, LV1-EF1a-EGFP) or without viral accessory proteins
(second-generation, LV2-EF1a-EGFP) were compared (n = 8
experiments/packaging system). D. Alternative pseudotyping of LVs
was performed to determine its effects on transduction efficiency (n
= 4 experiments/pseudotype). The envelope coat proteins analyzed
were as follows: 1) vesicular stomatitis virus G protein (VSV-G); 2)
rabies SAD glycoproteins (RABSAD); 3) glycoprotein from rabies virus
PV strain (RABPV); and 4) lymphochoriomeningitis virus envelope
(LCMV). Post hoc differences between vectors are represented by
bars; * p < 0.001.
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In addition, EGFP expression in DRG cultures was also
noted in small non-neuronal cells that appeared spindle-
shaped with long processes, typical of cultured glia cells,
as well as in a few cells typical of fibroblasts [26].
Expression of EGFP remained stable during the lifespan
of the cultures, typically more than two weeks.
On the basis of these initial observations, quantitative
comparison of in vitro vector performance on disso-
ciated DRG neurons was analyzed using a set of Opti-
Prep-purified and titer-adjusted lentivectors at MOI =
20 for 5-DIV after the initial exposure. Specifically,
transduction activities of different cellular promoters
were tested, including the EF1a promoter (VSV-G
EF1a), the CAG promoter (VSV-G CAG), and the UbC
promoter (VSV-G UbC). These promoters had exhibited
strong (EF1a), medium (CAG), and weak (UbC) activity
in driving EGFP expression in 50B11 cells, respectively.
Additionally, the relative transduction efficiency of two
pseudotypes, VSV-G and RABPV, were also compared
using LV2-EF1a-EGFP, since these showed the best
(VSV-G) and the second best (RABPV) performance in
transducing 50B11 cells. The results (Figure 2) demon-
strated that VSV-G EF1a vector produced the highest
neuronal transduction rate (70 ± 7%, n = 4), followed by
RABPV EF1a (58 ± 6%, n = 4), VSV-G CAG (48 ± 7%,
n = 4), and VSV-G UbC (29 ± 10%, n = 4). Differences
between vectors reached significance in all groups (p <
0.001, Figure 3). These results in primary DRG cultures
verified a similar variability in transgene expression
directed by these promoters as in the test using 50B11
cells (Figure 1). These findings suggest that VSV-G
pseudotyped lentivector incorporating human EF1a pro-
moter would be the optimal candidate among the tested
vectors for in vivo gene transfer to the relatively quies-
cent cells in the DRG of adult rat.
In addition to neuronal transduction, all these vectors
supported robust transgene expression in non-neuronal
cells in DRG cultures. Interestingly, although there was
no significant difference in glial transduction rates
between the various lentivectors (12 ± 2%, 9 ± 2%, 12 ±
7%, and 10 ± 4% for VSV-G UbC, VSV-G CAG, VSV-G
EF1a,a n dR A B P VE F 1 a, respectively), all four tested
lentivectors showed significantly lower transduction
rates for glia compared to neuronal cells (p < 0.001, Fig-
ure 3). This is despite the fact that neurons represent
only ~5% of the total cellular population under our cul-
ture conditions at 5-DIV.
In vivo assessment of lentivector-mediated gene transfer
into DRG in adult rats
Successful transgene expression in vivo will be required
to take maximal advantage of research and therapeutic
applications of vector technology. We therefore
investigated factors that might influence in vivo DRG
transduction, including accessory genes, vector pseudo-
typing, and site of injection.
Influence of accessory genes on in vivo transduction after
DRG injection
Because VSV-G pseudotyped EF1a-EGFP was demon-
s t r a t e dt ob eag o o dc a n d i d a t ev e c t o rb yin vitro studies,
we therefore focused on this vector for our in vivo studies
of EGFP transgene expression after delivery through
direct injection into DRGs. An average total of 1.68 × 10
6
TU for purified VSV-G pseudotyped EF1a-EGFP pre-
pared using the second-generation packaging construct
(LV2-EF1a-EGFP), or 1.44 × 10
6 TU for purified EF1a-
EGFP prepared using the first-generation packaging con-
struct (LV1-EF1a-EGFP), were injected in a volume of 2
μl into the fifth lumbar (L5) DRGs. Two out of 24 DRGs
harvested at 2-weeks following exposure to the VSV-G
pseudotyped LV2-EF1a-EGFP showed only very dim and
scattered EGFP signals in sections (data not shown).
However, transduction performance assessed four weeks
after vector application (n = 10 of 12 ipsilateral DRGs
injected by VSV-G pseudotyped LV2-EF1a-EGFP and n
= 8 of 10 ipsilateral DRGs injected by VSV-G pseudo-
typed LV1-EF1a-EGFP) revealed EGFP fluorescence of
neuronal somata and axons. Representative images (Fig-
ure 4A), photographed from a section of DRG injected
by VSV-G pseudotyped LV2-EF1a-EGFP, shows immu-
nostained EGFP expression, which are colocalized with
b3-tubulin (Figure 4B), whereas EGFP signal is absent in
contralateral DRGs (n = 6, Figure 4E), demonstrating
that VSV-G pseudotyped EF1a-EGFP is capable of trans-
ducing DRG cells in vivo with anatomic selectivity. Fluor-
escence was also evident in axons both among somata
and also in axon fascicles. In ~50% of the injections,
weak EGFP signals were detected in nerve roots, variably
both ventral and dorsal, proximal to the injection (Figure
4C), and in the spinal nerve distal to the injection (Figure
4D). Identification of EGFP by immunohistochemistry
did not reveal any signals in the corresponding spinal
cord segment (n = 4, data not shown), indicating ana-
tomic selectivity of transduction with lentivector admi-
nistered directly to an individual DRG. The transduction
levels appeared to be independent of the generation of
the lentivector packaging system. Specifically, using
either the first- or second-generation packaging system
resulted in 19 ± 9% in the VSV-G pseudotyped LV1-
EF1a-EGFP and 20 ± 8% in the VSV-G pseudotyped
LV2-EF1a-EGFP (P > 0.05) of EGFP expressing profiles
per total neurons within the field, respectively (Figure
4F). As confirmation of the IHC data, EGFP expression
in DRG homogenates was also detected by immunoblots
(Figure 5). There was no structural change or infiltrate
evident in the DRG apparent by hematoxylin/eosin stain-
ing (n = 3 DRGs, data not shown).
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from adult rats were transduced at MOI = 20 using VSV-G pseudotyped lentivectors encoding EGFP driven by UbC, CAG, and EF1a promoters, or
using RABPV pseudotyped EF1a-EGFP, all packaged by the second-generation system. Cultures were maintained 5-DIV before colocalization
immunofluorescence (IF), cell identification, and quantitative analysis. Representative images of the EGFP-expressing dissociated DRG cultures( A,
B, C, and D) and their correspondent b3-tubulin IF images (E, F, G, and H) revealing neuronal patterns, merged data for identification of EGFP-
positive neurons (I, J, K, and L), phase-contrast images captured in the same fields (M, N, O and P), and higher magnification images showing
neuronal somata and neurite projections in transduced neurons (Q, R, S and T), as well as transduced non-neuronal cells colocalized with
glutamine synthetase (U, V, W and X), are shown in the panels of far-left column for VSV-G UbC, the second-left column for VSV-G CAG, the
second-right column for VSV-G EF1a, and the far-right column for RABPV EF1a. Filled arrows point to transduced neurons, empty arrows to non-
transduced neurons, filled arrowheads to transduced neuronal projections, and empty arrowheads to transduced glia. Scale bars = 100 μm.
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after DRG injection
Immunofluorescent double labeling was next performed
to characterize sensory neuron subpopulations expres-
sing EGFP in DRGs. L5 ipsilateral DRG sections from
VSV-G pseudotyped LV2-EF1a-EGFP injection were
labeled with antibodies against relevant markers of neu-
ronal subpopulations and glia, and assessed for colocali-
zation with EGFP (Figure 6). EGFP-positive cells were
co-localized with b3-tubulin, a general marker for neu-
rons (Figure 6C). Co-localization was not observed with
glutamine synthetase, a marker for satellite glial cells
(Figure 6R). Thus, our findings indicate that although
the VSV-G-pseudotyped vectors have a broad capacity
to transduce a variety of cell types in vitro, there is pre-
ferential transduction of neuronal phenotypes in vivo.
EGFP-transduced neurons included co-labeling with
markers that identify various neuronal subpopulations.
Isolectin B4 (IB4), which recognizes small (23 ± 4 μm
diameter in our samples), nonmyelinated non-peptider-
gic nociceptive neurons (Figure 6I), is bound by 36 ±
16% of transduced neurons expressing EGFP. a-Calcito-
nin gene-related peptide (CGRP), which recognizes
small (23 ± 5 μm), nonmyelinated peptidergic nocicep-
tive neurons (Figure 6L), is expressed by 34 ± 16% of
transduced neurons. Transient receptor potential vanil-
loid 1 (TRPV1), which selectively labels nociceptive neu-
rons (diameter 23 ± 6 μm) that are either myelinated or
nonmyelinated (Figure 6O), was detected in 27 ± 8% of
transduced neurons. Neurofilament 200 (NF200; Figure
6F), which identifies myelinated neurons, was detected
in 40 ± 4% of EGFP-expressing neurons. The transduced
population of NF200-positive neurons had diameters (28
±1 2μm) that were not significantly less than those that
were EGFP-negative (32 ± 12 μm; P = 0.1), and included
l a r g ea sw e l la ss m a l ln e u r o n s. In general, the lentivec-
tors showed an ability to transduce a broad population
of DRG neuronal phenotypes. Transduction efficiencies
within the different subpopulations did not differ
(TRPV1: 16 ± 9%; IB4: 25 ± 8%; CGRP: 29 ± 12%;
NF200: 17 ± 7%).
DRG injection of RABPV-pseudotyped lentivector for in vivo
transduction
We also studied DRG sensory neuron gene transfer by
RABPV pseudotyped LV2-EF1a-EGFP vector directly
injected into the DRG. Results showed that RABPV len-
tivector (2.16 × 10
6 TU of purified vector) resulted in
similar transduction patterns to those of VSV-G vector,
with EGFP expression predominantly in 15 ± 3% (N =
3) DRG neurons and in the nearby nerve roots and
spinal nerve (Figure 7).
RABPV-pseudotyped lentivector injection into distal muscle
for DRG transduction
Lentivectors pseudotyped by Rabies G have demon-
strated particular efficacy in transducing spinal cord
motor neurons via retrograde transport after peripheral
injection into muscle [20]. We therefore examined
whether RABPV pseudotyped LV2-EF1a-EGFP might
transduce DRG neurons following such injections. Four
weeks after gastrocnemius muscle injection of 2.08 ×
10
7 TU of RABPV EF1a vector, EGFP signal was detect-
able only in the ipsilateral gastrocnemius fibers (Data
not shown), and no EGFP expression was observed in
either ipsilateral or contralateral DRGs (Figure 7). This
suggests that vector access to peripheral sensory neu-
rons is limited after intramuscular injection of lentivec-
tors, and that intramuscular injection, although effective
in delivery to spinal cord motor neurons [20], is not a
desirable route for DRG gene transfer by lentivectors.
Behavioral evaluation after injection and transduction
Inflammatory changes in the DRG are associated with
hyperalgesia in various models of neuropathic pain.
Although lentivectors are unlikely to initiate a substan-
tial inflammatory response, we nonetheless examined
sensory behavior following injection to identify if viral
infection can itself produce manifestation of animal
pain. We gauged hyperalgesia by the incidence of a
characteristic behavior not seen in normal animals, spe-
cifically sustained, complex foot withdrawal with lifting,
shaking, or grooming following a noxious punctate
mechanical stimulation (a pin touch) to the plantar sur-
face of the hind paw. This method has been validated in
neuropathic pain [27], and has been shown to represent
Figure 3 Quantitative analysis of lentivector transduction
efficiency in primary DRG cultures. Quantification of transduction
rates for neurons (identified by b3-tubulin antibody) and glia
(identified by glutamine synthetase antibody) in primary dissociated
DRG cultures demonstrated vector-specific efficacy for VSV-G
pseudotyped vectors containing UbC, CAG, and EF1a promoters
and a RABPV pseudotyped vector with the EF1a promoter. Post hoc
differences between transduction rates are represented by bars; * p
< 0.001. (There were no differences in glial transduction rates
between the different vectors.)
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avoidance [28]. DRG saline injections produced a mild
hyperalgesic state (Figure 8) in which up to 14 ± 11% of
touches produced a hyperalgesic response, which
resolved by 42 days. VSV-G pseudotyped second-gen-
eration lentivectors and RABPV pseudotyped second-
generation lentivectors produced a mild but sustained
increase in hyperalgesia behavior, whereas VSV-G pseu-
dotyped first-generation lentivectors caused no
difference in behavior compared to baseline. These pat-
terns were statistically different (repeated measures
ANOVA P < 0.05 for interaction of injection Group x
Time).
Discussion
Chronic pain, particularly neuropathic pain, has proved
resistant to conventional pharmacological approaches.
Systemic administration of agents that reverse neuronal
Figure 4 VSV-G pseudotyped EF1a-EGFP lentivector-mediated gene transfer into dorsal root ganglion in adult rat. A, B. Representative
images of immunostained EGFP expression (A) and EGFP-expressed neurons co-labeled with b3-tubulin (DRG neuronal marker, B) 4 weeks after
injection of the LV2-EF1a-EGFP into a L5 DRG. C, D. Arrows point to weak EGFP expression in nerve roots proximal to the injection (C) and
spinal nerve distal to the injection (D). No EGFP staining was detected in corresponding spinal cord (not shown) or in contralateral DRGs (E; the
two vertical streaks are from wrinkles in the section). F. Bar graphs represent the percentage of immunostained EGFP positive neuronal cells per
total DRG neurons observed in the sections of L5 ipsilateral DRGs injected with VSV-G LV1-EF1a-EGFP (n = 3) and VSV-G LV2-EF1a-EGFP (n = 4).
Tissues were collected four weeks after vector injection. Scale bar = 200 μm for A, B, and E; 100 μm for C and D.
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their actions on normal neuronal function [29]. Even
neuraxial infusions result in widespread distribution in
the central nervous system, and also require implanta-
tion of complex hardware and ongoing specialized care.
Many segmental neuropathic conditions such as radicu-
lopathy, post-herpetic neuralgia, and those related to
tumor involvement or trauma, could be addressed by
anatomically targeted therapy. By this approach, specific
sensory pathways might be subjected to intensive func-
tional modulation while avoiding systemic side effects.
The DRG is an appealing therapeutic target. Unlike per-
ipheral nerves or the spinal cord, the DRG is tolerant of
needle penetration and injections [18], perhaps in part
due to its generous vascular supply [30]. Well-defined
clinical injection techniques are available for injecting
solutions within or adjacent to the DRG [18]. Further-
more, altered neuronal and glial function within the
DRG is a critical component of pain pathogenesis fol-
lowing injury or inflammation of peripheral nerves [31].
Advances in molecular therapies provide new oppor-
tunities for highly specific treatment of pain conditions.
For instance, therapeutic genes have been introduced
into DRGs by administration of viral vectors into the
cerebrospinal fluid of the spinal intrathecal space.
Although this mode of delivery would be easy to employ
clinically, clear limitations include unintended transduc-
tion of CNS structures [32,33], low efficiency rates for
DRG transduction [34], and uncertain penetration of
vectors to the distal pole of the DRG, which could be a
particular constraint in clinical settings considering the
large diffusion distances in a human DRG. In contrast,
direct injection into the DRG has achieved transduction
restricted to the DRG and high efficiency in experimen-
tal animals [34,35]. Although paresis has also been
noted [36], it is not known whether this is vector-
related.
Regarding the optimal vector for DRG transduction, it
is important to note that the primary types of viral vec-
tors used in previous studies for treating experimental
neuropathic pain have been largely episomal in nature,
namely adenovirus, herpes simplex virus type 1 (HSV-1)
and various serotypes of adeno-associated viruses
(AAV). The main drawback in the use of episomal viral
vectors, other than the specific vector-related problems,
is the potential for limited temporal expression pattern
for the transferred gene of interest. For adenoviral vec-
tors, transient vector persistence and transgene expres-
sion is largely attributed to the host immune activation
due to the presence of early viral gene products in the
vector system [37]. However, investigators have designed
a helper-dependent or “gutless” adenoviral vectors in
which all of the immunogenic viral genes are removed
[38-40]. The application of these newer versions of the
adenoviral vector to the DRG is now emerging [41].
One of the classic viral vector systems employed to
transduce DRG neurons is based on HSV-1 [5,42]. The
administration of HSV-1 vectors has typically been
through peripheral inoculation, which takes advantage
of the natural tropism of HSV-1 for the sensory neu-
rons. Although this vector has shown promise for effi-
ciently transducing these types of neurons, there are
specific limitations, which include the difficult and com-
plex nature of manipulating and generating this vector
system, vector-related toxicity [43], and potential for
conversion of the replication-defective virus into a com-
petent one, depending on the serum status of the
infected patients who may have been previously exposed
to wild-type HSV.
There is emerging new data investigating the utility of
AAV vectors as a therapeutic vehicle to the DRG. These
studies document highly efficient transduction of DRG
neurons following direct AAV injection into the rat DRG
[34,44]. Unlike the other episomal vectors, such as ade-
novirus and HSV-1, AAV suffers from a restricted packa-
ging capacity (less than 5 kb), potential induction of host
immune responses depending on the serotype in humans,
and problematic scalability in vector production [4].
To circumvent some of the issues related to the earlier
described episomal vector systems, lentivectors have been
studied as one of the primary gene therapy vehicles, since
its innate ability to integrate into the host genome
Figure 5 Immunoblotting analysis of EGFP expression in
ipsilateral DRG. Results in two ipsilateral DRGs (Inj. DRG in lanes 4
and 5) following VSV-G coated LV2 EF1a-EGFP vector, as well as a
non-injected DRG (lane 3). Lane 2 is the homogenate from HeLa
cells transduced by EF1a-EGFP vector as an EGFP positive control,
and lane 1 shows protein standards (MagicMark, Invitrogen).
Arrowheads point to the expected size bands for EGFP (top panel),
and a-tubulin (bottom panel) as loading control. The additional
band in the bottom panel (asterisk) indicates an additional tubulin
isoform in DRG.
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Page 8 of 17Figure 6 EGFP expression in subpopulations of primary sensory neurons following VSV-G pseudotyped EF1a-EGFP vector injection
into DRG. 4 weeks after VSV-G LV2-EF1a-EGFP vector injection ipsilateral DRG sections were immunostained with EGFP antibody (green, A, D,
G, J, M, P) to detect EGFP expressing cells. Neurons were identified by staining for b3-tubulin (b3-Tub, red, B). Neurofilament 200 (NF200, red, E)
labeled myelinated neurons, isolectin IB4 (IB4, red, H) labeled non-peptidergic small neurons, a-calcitonin gene-related peptide (CGRP, red, K)
labeled peptidergic small neurons, and transient receptor potential vanilloid 1 (TRPV1, red, N) labeled nociceptive neurons. Satellite glia were
labeled with glutamine synthetase (GS, red, Q). Arrowheads are examples of EGFP-immunoreactive cells double labeled for a given neuronal
marker, evident in the overlays (yellow, C, F, I, L, O). In P, Q, and R, the arrowheads denote EGFP-immunoreactive neurons negative for GS,
while the arrows indicates rings of satellite glial cells. Scale bar: 100 μm.
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Page 9 of 17Figure 7 Direct DRG injection (but not intramuscular injection) of RABPV pseudotyped EF1a lentivector induces EGFP expression in
the ipsilateral DRG. A, B. Representative images of EGFP expression in neurons and fibers (A, arrows point to neurons and filled arrowheads to
fibers) revealed by EGFP IHC and EGFP-expressing neurons and fibers co-labeled with b3-tubulin (B, arrows point to neurons and filled
arrowheads to fibers) 4 weeks after direct DRG injection of the RABPV coated LV2-EF1a-EGFP. C, D. Arrows point to EGFP expression in spinal
nerve distal to the injection (C) and in nerve roots proximal to the injection (D). High magnification shows predominant expression of EGFP in
neurons, and no colocalization to glutamine synthetase, a marker for satellite glial cells (E and F, arrows point to transduced neurons, filled
arrowheads to EGFP positive fibers, and empty arrows to glial cells). G, H. No EGFP expression was detected in the ipsilateral DRG 4 weeks after
gastrocnemius muscle injection of RABPV pseudotyped LV2-EF1a-EGFP, shown in the representative image of EGFP IHC (G) and corresponding
phase-contrast image (H). Scale bars = 200 μm for A, B, = 100 μm for C, D, G, H, and = 50 μm for E and F.
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Page 10 of 17following cell entry provides the potential for persistent,
long-term expression following a single administration
[8,45]. Moreover, lentivectors have shown an enhanced
propensity to transduce terminally differentiated tissues
from neuronal origin [46,47] as demonstrated in the initial
discovery by Naldini et al. [8], with negligible inflamma-
tion [8,20]. The packaging capacity of the lentivector sys-
tem is relative large (~12-15 kb) [48] and would be
suitable for cloning a large majority, if not all, of the cur-
rently transferred genes currently undergoing testing in
pre-clinical and clinical trials.
In our hands, we successfully transduced DRG neurons
using replication-defective lentivectors at ~20% effi-
ciency, which is in contrast with a previous study by
Mason et al. [35], who estimated much lower levels of
transduction (1-2%). The reasons for the higher trans-
duction efficiencies in our study are not clear. Although
there are several similarities between the methodologies,
such as the same packaging plasmids (pCMVΔR8.74),
envelope coat protein, and injection methods in the
DRG, a major difference was the time point used to ana-
lyze the tissue following lentivector administration. Our
study analyzed the DRG tissues at 4 weeks, whereas
Mason et al. [35] examined their tissues at 2 weeks fol-
lowing lentivector injection. In earlier unpublished
experiments in our lab, we observed little to no EGFP
expression in the DRG 1-2 weeks after injection, which is
consistent with the Mason et al. study [35]. It is not clear
why EGFP expression following lentivector transduction
in the DRG is slow in onset, in contrast to many observa-
tions in other mammalian organ systems that demon-
strate rapid expression from integrated lentivectors
[45,49]. A second explanation for differences between
our findings and those by Mason et al. [35] could be the
difference in the internal promoter used within the lenti-
vector system. We used an EF1a promoter whereas
Mason et al. used a CMV promoter, which may drive
transgene expression in DRG neurons with different
strength and temporal activity. Finally, semi-purification
of lentiviral particles via OptiPrep ultracentrifugation in
our study may also impact the transduction efficiency for
in vivo applications by removing factors that negatively
affect the functionality of the vector [50].
To assess whether a loss of viral accessory genes would
be one of the rate-limiting factors delaying the transgene
expression by the integrated lentivectors or negatively
affect the transduction efficiency to the DRG, we investi-
gated whether including the full complement of viral
accessory genes, specifically vif, vpr, vpu, nef, tat and rev,
would have a beneficial role. However, no positive effect
on the count of EGFP(+) DRG neurons was calculated
following the 4 week injection period by the early-genera-
tion lentivectors. The lack of a requirement for viral
accessory proteins is consistent with previous in vivo stu-
dies demonstrating equally efficient transduction using
first- or second-generation lentivectors in mouse hepato-
cytes [17] or rat brain [8]. However, our preliminary
behavioral findings suggest that hyperalgesia may be
diminished after injection of first-generation vector. This
suggests that including the accessory genes may have
immune suppressing effects in addition to their role in
viral production [17], although the possible added safety
of the second generation vector may make this a more
desirable choice for translational development.
Although the effectiveness of the lentivector system in
our study has equal, or even greater, efficiency than pre-
viously described episomal viral systems, it is naïve to
believe that the lentivector system does not have its own
inherent challenges. First, it is not clear whether inser-
tional mutagenesis will arise following integration, as
has been observed in previous clinical trials using simple
retroviral vectors based on murine leukemia virus
(MLV) [51-53]. However, numerous studies have been
published demonstrating that the integration pattern of
lentivectors differs from that of the MLV-based vectors
[54], so this may not end up becoming a major issue.
Other vector systems considered to be largely episomal,
including AAV, are also susceptible to the risk of inser-
tional mutagenesis. Specifically, Nakai et al. [55] showed
that this vector system is also promiscuous in its inte-
gration pattern, which may lead to oncogenesis [56].
Second, the role of the host immune system in dimin-
ishing lentiviral transduction and/or transgene expres-
sion needs further investigation [37]. Finally, since in
vivo gene transfer into the DRG using lentivectors by
our approach only allows for injection of very small
Figure 8 Pain behavioral evaluation after DRG injections.T h e
rate of hyperalgesic response to noxious punctate mechanical
stimulation transiently increases for animals injected with vehicle
(saline + polybrene 100 nM, n = 5), and is minimally affected by
VSV-G pseudotyped first-generation lentivector (VSV-G LV1-EF1a-
EGFP; n = 10). However, there is a persisting increase after injection
of VSV-G pseudotyped second-generation lentivector (VAV-G LV2-
EF1a-EGFP; n = 8), or RABPV pseudotyped second-generation
lentivector (RABPV LV2-EF1a-EGFP; n = 5). Data are shown as mean
± SD. P < 0.05 for ANOVA interaction Group X Time.
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higher titer than used in this study) and purified pre-
parations may required for improved gene transfer [57].
In the clinical setting, many clinical neuropathic pain
conditions have a segmental presentation, such as nerve
trauma, herpes zoster, and tumor involvement, making
anatomically focused treatment an appealing option.
Standard techniques for delivering agents into the
immediate vicinity of the DRG are well established [58],
and injection within the DRG is well tolerated [18].
Numerous applications may be envisioned for gene
transfer into the DRG. In the area of experimental neu-
ropathic pain research, a myriad of pathogenic triggers
and downstream effectors have been proposed [31],
often based on imperfect pharmacology in ex vivo mod-
els. Modulating genetic events at the level of the DRG
in behaving animals would provide a new level of ana-
tomic and molecular specificity that may clarify which
cellular events are causative in neuropathic pain. In clin-
ical applications, expression in the DRG of secretable
analgesic peptides such as neurotrophic factors (e.g.
GDNF, VEGF), anti-inflammatory peptides (e.g. IL-4, IL-
10, IL-14, fractalkine), inhibitory neurotransmitters (e.g.
enkephalin, endomorphin-2), or soluble TNF-a receptor
may be most effective, since transduction of all neurons
is not a prerequisite for effective treatment. Specifically,
the approximately 20% transduction efficiency we
demonstrate in our experimental model may be suffi-
cient for providing adequate peptide levels to modulate
the performance of all neurons within a ganglion. Alter-
native approaches may include modulation of intracellu-
lar or neuronal membrane peptides through RNAi
knockdown of nociceptive-specific targets (e.g. CGRP,
NaV1.7, NaV1.8, NF-B) or overexpression of a natu-
rally analgesic peptide (μ opioid receptor), although the
efficacy of this approach would be tightly tied to trans-
duction efficiency.
In conclusion, our study clearly demonstrates that the
VSV-G pseudotyped lentivector system can be effectively
utilized for genetic modification of sensory neurons in
vivo. It remains to be explained why the lentivector sys-
tem expresses the transgene in a delayed manner in
comparison to previously published observations in
other organs. Nonetheless, our findings suggest that len-
tivectors delivered to the DRG could be readily
employed not only in the study of basic pain mechan-
isms, but potentially in the treatment of clinical neuro-
pathogenic pain.
Methods
Animals
Sprague Dawley rats (5-6 weeks old; 125-150 g body
weight) were purchased from Charles River Laboratories
(Wilmington, MA). All animal procedures were
approved by the Zablocki VA Medical Center Animal
Studies Subcommittee and Medical College of Wiscon-
sin IACUC. All rats were allowed ad libitum access to
food and water prior to and throughout the experimen-
tal protocol.
Lentivector production and purification
Lentivector transfer plasmids
The lentiviral transfer vector plasmids used in this study
expressed the enhanced green fluorescent protein
(EGFP) and was modified to include cis-acting DNA ele-
ments that would promote increased transduction effi-
ciency and transgene expression. Each of the transfer
plasmids contained central polypurine tract sequences 5’
to the promoter and woodchuck post-regulatory ele-
ments 3’ to the transgene. In addition, the transfer plas-
mids had 3’ LTR deletion to minimize promoter activity
and lead to self-inactivation following integration. These
changes to the transfer plasmids are described in the
references for each construct: 1) pEF1a-EGFP (Addgene
plasmid 12255) has the elongation factor 1a promoter;
2) p156CAG-EGFP (provided by Dr. Inder Verma, Salk
Institute) was described previously [59] and contains the
composite hybrid chicken b-actin promoter fused with
CMV enhancer elements; 3) pHR(+).c.UbC.EGFP.R(-)W
(+) contains the human Ubiquitin C promoter [60]; and
4) pHR(+).c.mPGK.EGFP.R(-)W(+) contains the mouse
phosphoglycerate kinase 1 (PGK) promoter and was
cloned using standard cloning techniques.
Packaging and envelope plasmids
The packaging plasmids used in this study were either
first-generation (pCMVΔR8.2) [8] or second-generation
(pCMVΔR8.74) [61]. The envelope plasmids are as fol-
lows: 1) pVSV-G contains the vesicular stomatitis virus
G protein; 2) pLCMV-GP contains the lymphochorio-
meningitis virus envelope [62]; 3) pCEF-rabies PV con-
tains the glycoprotein from rabies virus PV strain
(RABPV) [63]; and 4) pCEF-rabies SAD (B19) contains
the rabies SAD glycoprotein (RABSAD) [64].
Lentivector production, purification and titering
Briefly, human embryonic kidney 293T cells (ATCC)
were triple-plasmid transfected into 100 mm dishes
using the calcium phosphate method previously
described by us [17,60,65] using chloroquine (25 μM).
The three plasmids transfection protocol consisted of a
combination of a transfer plasmid (10 μg), packaging
plasmid (6.5 μg) and envelope plasmid (3.5 μg) per dish.
The media was replaced 12-16 hours after the initial
transfection, and then 24-48 hours later, the superna-
tants were collected, pooled when applicable, and
cleared by slow speed centrifugation at 1,500 rpm for 5
minutes. Subsequently, the conditioned media was fil-
tered through a 0.45-μmp o r e ,a n de i t h e rf r o z e ni na l i -
quots at -80°C or if concentration was necessary, the
Yu et al. Molecular Pain 2011, 7:63
http://www.molecularpain.com/content/7/1/63
Page 12 of 17filtered conditioned media was centrifuged at 23,000
rpm for 2 h in a swinging bucket rotor (SW28 Beckman,
Fullerton, CA). The final pellet was resuspended in Ca
2
+/Mg
2+ free phosphate buffered saline (PBS). For the in
vitro primary DRG dissociated cell cultures and in vivo
injections, the lentiviral particles were further purified
by a modified OptiPrep (Sigma-Aldrich, St. Louis, MO)
density gradient ultracentrifugation [50]. OptiPrep was
used due to its demonstrated safety in human clinical
trials [66]. Briefly, the concentrated lentivector prepara-
tions in 5 ml PBS were mixed with equal volume of 60%
OptiPrep to yield a 30% OptiPrep solution, and then 2
ml of 5% OptiPrep (in PBS) was laid on top. The gradi-
ent was spun at 37,000 rpm in a Beckman ultracentri-
fuge using a SW 41Ti rotor for 2 h at 4°C. Lentiviral
particles formed a buoyant dense band at 5%/30% inter-
face and were collected. The collected fraction was
applied to a Centricon (100-cutoff) filter, centrifuged for
10 min at 10,000 × g until ~100 μl remained. The final
product was stored in aliquots at -80°C or used immedi-
ately for injections. Functional titers were determined by
limiting dilution on HeLa cell (2 × 10
5 cells/well) in the
presence of polybrene (8 μg/ml). The transduced HeLa
cells were compared to a reference naïve HeLa cell line
and analyzed by fluorescence-activated cell sorting
(FACS) analysis. The titers were calculated as transduc-
tion units (TU) per ml. Each of the lentivector batches
utilized in our experiments had comparable titers ran-
ging from 7.6 × 10
5 to 1.6 x10
6 TU/ml (conditioned
media) for in vitro experiments using 50B11 cells and
from 3.43 × 10
8 to 2.65 × 10
9 TU/ml (purified concen-
trated vectors) for in vitro primary DRG dissociated cell
cultures a n di nv i v oinjections. The lentivector suspen-
sions were briefly centrifuged and kept on ice immedi-
ately before exposing to cells and injection to the rats.
Transduction of cultured DRG neurons
Immortalized dorsal root ganglion sensory neuronal cell
(50B11) cultures
50B11 cells are immortalized DRG neuronal lines from
embryonic day 14.5 rats, and were kindly provided by
Dr. Ahmet Höke (Department of Neurology, Johns Hop-
kins University). The 50B11 cells have been reported to
phenotypically exhibit characteristics similar to that of
nociceptive neurons [21,22]. 50B11 cells were grown to
70% confluence and maintained in DMEM/F12 medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin-100 μg/ml
streptomycin, 0.2% glucose, 0.5 mM L-Glutamine, 1X B-
27 supplement (Invitrogen). Neuronal differentiation of
50B11 cells were induced by addition of 50 μMo ff o r -
skolin (Sigma-Aldrich) in the culture medium [21]. Cell
monolayers were fixed in 10 min with 4% paraformalde-
hyde, permeablized for 1 h with 0.5% Triton X-100, and
then stained for DRG neuronal markers by a standard
immunofluorescence protocol as described below using
antibodies against CGRP, TRPV1, and b3-tubulin, or
isolectin IB4 binding. For lentiviral transduction, cells
were plated at a density of 1 × 10
5 cells per well onto
24-well plates for 24 h. Cultures were serially transduced
over a two day period (one transduction per day) with
conditioned media containing the various modified len-
tivector systems at a MOI of 1 at each infection in the
presence of polybrene (8 μg/ml of culture medium).
A f t e rf o u rd a y sin vitro, cells were collected, and the
transduction efficiency by the lentivectors in the 50B11
cells was analyzed by FACS.
Dissociated DRG cell culture and lentivirus transduction
Cultures of rat DRG neurons were prepared as
described previously [67] with some minor modifica-
tions. In brief, DRGs from the lumbar segments of male
Sprague Dawley rats were obtained under sterile condi-
tions. DRGs were cut into approximately 2 mm sections,
and digested in a collagenase mixture (0.5 mg/ml; Liber-
ase Blendzyme 2; Roche, Indianapolis, IN) dissolved in
serum-free DMEM at 37°C for 30 min. Digested ganglia
were collected by centrifugation at 1,000 × g for 5 min
and dissociated in 0.25% trypsin mixed with serum-free
D M E Mf o r3 0m i n u t e su n d e rt h es a m ec o n d i t i o n s
described earlier. At the end of the 30 minutes, the tryp-
sin was inactivated by adding soybean trypsin inhibitor
(5 mg/ml). The dissociated-cell suspension was centri-
fuged at 1,000 × g for 5 min, and the resulting pellet
was resuspended in pre-warmed serum-free growth
medium (Neurobasal A; Invitrogen, Carlsbad, CA) sup-
plemented with B27, 100 U/ml penicillin-100 μg/ml
streptomycin, 5 mM glutamine and 30 ng/ml NGF-b). A
single cell suspension was achieved by gentle titration
and plating onto poly-L-lysine coated glass coverslips.
Cultures were transduced with OptiPrep-purified and
various modified lentivectors in the presence of poly-
brene (4 μg/ml of culture medium) 10 h after cultures
were established. Eighteen hours after the onset of
transduction, the viruses were removed and were
replaced with supplemented neurobasal medium. After
five days in vitro, direct EGFP fluorescence was exam-
ined and photographed under an inverted Nikon
TE2000-S epifluorescence microscope attached to an
Imaging camera MicroFire Picture Frame imaging soft-
ware (Optronics Microfire, Santa Barbara, CA). Images
were analyzed and processed in Adobe Photoshop CS3.
To accurately determine the transduction efficiency of
various lentivectors on neurons or glial cells in disso-
ciated adult rat DRG cultures, four independent vector-
treated cultures were stained using either neuron-speci-
fic b3-tubulin monoclonal antibody or rabbit anti-gluta-
mine synthetase (GS) antibody, a ubiquitous satellite
g l i a lc e l lm a r k e r .I no r d e rt od e r i v et h ep e r c e n t a g eo f
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neuronal cells visible in 5 randomly fields (10×) per cul-
ture well was counted, cells showing colocalization with
b3-tubulin were determined using color overlay on indi-
vidual images, and the mean percentages of EGFP/b3-
tubulin positive neuronal cells were calculated. For
counting glial cells following GS immunostaining, the
fluorescent dye Hoechst 33342 (0.25 μg/ml, Invitrogen)
was used for nuclear staining to correctly distinguish the
glial cells based on their smaller nuclear bodies and
high-density staining by Hoechst from the other cells
(neurons and fibroblasts with larger but lightly stained
nuclei) in the culture wells, EGFP positive glial cells
colocalized with GS in the merged pictures were
counted in 5 randomly fields (20×) per culture well, and
results represented by average percentage of colocaliza-
tion with GS.
Injection of lentivectors in vivo
The DRG microinjection of lentivectors was performed
as previously described [19]. In brief, male Sprague Daw-
ley rats were anesthetized under isoflurane, and subse-
q u e n t l yal o w e rl u m b a ri n c i s i o nw a sm a d eaf e w
millimeters to the right of the midline. The paraspinal
muscles were separated to expose the lateral aspect of
the L4 and L5 vertebrae and their transverse processes,
exposing the L4-L5 intervertebral foramen for injections
of the L5 DRGs. After exposure, the intervertebral fora-
men was enlarged by removal of laminar bone, exposing
the distal half of the ganglion. A micropipette was
advanced approximately 100 μm into the ganglion and
held in position for 3-5 min. Injections contained either
lentivectors (2 μl) or saline (2 μl), in both cases contain-
ing polybrene (100 ng), which has been used as a stan-
dard reagent to improve in vivo transduction with
lentivectors [68-70]. Injection was performed over a 5
min period using a Nanoliter 2000 microprocessor-con-
trolled injector (World Precision Instruments, Sarasota,
FL). The pipette remained in place for 5 min to allow the
pressure within the gangliont oe q u a l i z e ,a n dt h e nt h e
pipette was slowly removed. Muscles and fascia were
closed using 4-0 chromic gut suture and the skin was
closed with staples. Unilaterally left gastrocnemius mus-
cle injection was performed in rats using a microsyringe
fitted with a 30-gauge needle (Hamilton) [20], inserted
through the skin. Injected solution consisted of 20 μlo f
RABPV pseudotyped EF1a-EGFP lentivector containing
a total of 2.08 × 10
7 viral particles (TU) over 90s.
Characterization of EGFP expression
Immunohistochemistry (IHC) and Imaging
Four weeks after injection, animals were terminally
anesthetized and transcardially perfused with 4% parafor-
maldehyde (PFA) in PBS. DRGs and spinal cord
segments, as well as gastrocnemius muscle (RABPV
EF1a-EGFP injection) were dissected, post-fixed in 4%
PFA, and processed for paraffin embedding and section-
ing. Detection of EGFP in tissue sections was performed
by EGFP immunohistology in order to achieve an
improved signal-to-noise resolution compared to direct
detection of EGFP fluorescence. The EGFP signal on
DRG sections was detected using a primary mouse anti-
EGFP antibody (1:400, Santa Cruz Biotechnology (SCB),
Santa Cruz, CA), and subsequent incubation with Alexa
Fluor 488-conjugated donkey anti-mouse second anti-
body (1:2,000, Jackson ImmunoResearch, West Grove,
PA). IHC enhanced EGFP signals were co-labeled using
the following antibodies: mouse anti-b3-tubulin (1:400,
SCB), mouse anti-a-calcitonin gene-related peptide
(CGRP, 1:100, SCB), rabbit anti-vanilloid receptor sub-
type 1 (TRPV1, 1:200, Thermo-Fisher scientific, Pitts-
burgh, PA), mouse anti-neurofilament 200 (NF200,
1:1,000, Sigma-Aldrich), and rabbit anti-glutamine
synthetase (GS, 1:600, SCB). For co-localization, primary
antibodies were revealed by the appropriate 549-conju-
gated secondary antibodies (1:2,000, Jackson ImmunoRe-
search). Non-peptidergic neurons were labeled using
biotinylated griffonia simplicifolia Isolectin B4 (IB4) (10
μg/ml, Invitrogen) coupled to Alexa Fluor 549-conju-
gated Streptavidin (1:6,000; Jackson ImmunoResearch).
Standard fluorescent immunohistochemistry techniques
were used for all protocols as described previously
[71,72], with BSA replacement of first antibody as the
negative control. Briefly, paraffin sections (5 μmt h i c k )
were deparaffinized in xylene, rehydrated through graded
alcohol, and processed for antigen retrieval by heating
the sections at 95°C in 10 mM sodium citrate (pH 6.0)
for an initial 5 min and for two successive 5 min periods.
Endogenous autofluorescence was suppressed by dipping
of slides in 2% picric acid for 10 min. After washing, sec-
tions were blocked with 3% BSA for 1 h at room tem-
perature, and then incubated overnight at 4°C with
primary antibody or biotinylated IB4 diluted in 3% BSA.
Sections were then washed in PBS, incubated for 1 h at
room temperature (RT) with corresponding 549-conju-
gated secondary antibody, or 549-conjugated streptavi-
din, diluted in 1% BSA, and then dehydrated through an
ethanol series to xylene and mounted. The sections were
examined and images captured under a Nikon TE2000-S
fluorescence microscope with filters suitable for selec-
tively detecting the fluorescence of 488 (green) and 549
(red) or were examined under a light microscope. For co-
localization, images from the same section but showing
different antigen signals were overlaid.
Immunoblotting of EGFP protein in transduced DRG
samples
DRG tissue was harvested following transduction with
VSV-G lentivectors carrying the EF1a-EGFP cassette
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extracted using 1X RIPA buffer (150 mm NaCl, 2 mm
EDTA, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1%
SDS, 50 mm NaF, 10 μg/ml aprotinin, 10 μg/ml leupep-
tin, 1 mm phenylmethylsulfonyl fluoride, and 20 mm
Tris-HCl buffer, pH 7.4). As a positive control for EGFP
expression, HeLa cells transduced with the same lenti-
vector was extracted at the same time. Protein concen-
tration determined by using the BCA kit (Pierce,
Rockford, IL). DRG and HeLa protein lysates (20 μg)
were size separated using a 4-12% gradient SDS-PAGE
gel, transferred to 0.22 μm nitrocellulose membrane,
and blocked in 5% skim milk. The blots were subse-
quently incubated overnight at 4°C with a polyclonal
rabbit anti-GFP antibody (1:1,000; Cell Signaling, Dan-
vers, MA) or mouse monoclonal anti-a-tubulin antibody
(1:1,000; SCB). Immunoreactive proteins were detected
by enhanced chemiluminescence (Pierce, Rockford, IL)
after incubation with either HRP-conjugated anti-rabbit
IgG (1:2000, SCB) or anti-mouse IgG (1:5,000; SCB).
Histological quantification
L5 DRGs from three to four animals were analyzed for
quantification. To evaluate transduction rates, every fifth
DRG section was selected from the consecutive serial
sections (7-10 sections for each DRG), and in each
selected section, the number of EGFP fluorescent cells
was counted and transduction efficiency was expressed
as the percentage of EGFP immunopositive cells in the
total neuronal profiles revealed by b3-tubulin [33,73].
Every section was photographed at fixed exposure set-
tings of 10× magnification in which most of neurons
(100~300 neuron profiles) in each section were covered,
by use of a Nikon TE2000-S epifluorescence micro-
scope. When counting, image contrast was adjusted
(Adobe Photoshop CS3) such that background levels
became inapparent, and the same cutoff level was used
for all images [74,75]. Rates for EGFP expression in neu-
ronal subpopulations were determined in a similar fash-
ion using specific antibodies in at least 3 sections. All
counting was done using a masked protocol and the
average from two observers was used for calculation.
Diameters were derived from the neuronal area
(=2

(area/π)) measured only in profiles for which a
nucleus was evident.
Behavioral analysis
Noxious punctate mechanical stimulation was per-
formed using the point of a 22 g spinal anesthesia nee-
dle, which was applied to the center of the paw with
enough force to indent the skin but not puncture it.
This was applied for 5 applications separated by at least
10s, which was repeated after 2 min, making a total of
10 touches [27]. For each application, the induced
behavior was either a very brisk simple withdrawal with
immediate return of the foot to the cage floor, or a sus-
tained elevation with grooming that included licking
and chewing, and possibly shaking, which lasted at least
1s, characteristic of hyperalgesic behavior [27]. The
degree of hyperalgesia was recorded as the percentage of
total touches that were of this second complex and sus-
tained type, which is also associated with aversion in a
conditioned place avoidance paradigm [28].
Data analysis
Data are expressed as means ± SD. The statistical signif-
icance of differences for the transduction efficiencies on
50B11 cells and primary DRG cell cultures by different
modifications was assessed by ANOVA, and significance
of in vivo transduction rates between LV1-EF1a-EGFP
and LV-EF1a-EGFP were analyzed by the unpaired Stu-
dent’s t-test, using Statistica (StatSoft, Tulsa, OK). Beha-
vioral changes over time in each group were analyzed by
repeated measures ANOVA.
Additional material
Additional file 1: Characterization and lentivector transduction of
immortalized DRG neuronal cells (50B11 cells). Phase images of
undifferentiated (A) and differentiated (B) 50B11 cells show neuronal-like
morphology with extension of axons after differentiation with forskolin.
Immunofluorescence images exhibit 50B11 cells stained with IB4 (C, red)
and TRPV1 (D, red) in undifferentiation, and 3-tubulin (E, green) and
CGRP (F, green) after differentiation. EGFP expression images of 50B11
cells 72 h after lentivector transduction (MOI = 2) show the relative
transduction activity of VSV-G pseudotyped lentivectors incorporating
various cellular promoters including EF1 (G), UbC (H), PGK (I), and CAG
(J), or lentivectors containing same EF1 promoter but pseudotyped with
different envelope glycoproteins including VSV-G (K), RABSAD (L), RABPV
(M), and LCMV (N). Scale bars = 100 μm.
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